Previous close | 5.38 |
Open | 5.54 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 5.31 - 5.54 |
52-week range | 1.75 - 11.00 |
Volume | |
Avg. volume | 30,187 |
Market cap | 261.935M |
Beta (5Y monthly) | 1.25 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.78 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 11.88 |
Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CESTPARIS and CAMBRIDGE, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the fourth quarter and full year ended December 31, 2023,
In this piece, we will take a look at the 11 best nanotechnology stocks to invest in. If you want to skip our introduction to the nanotechnology sector and how it covers a variety of applications ranging from healthcare to consumer technology, then you can skip ahead to read 5 Best Nanotechnology Stocks To Invest […]
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, April 10, 2024 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights,theoretical1Total voting rights, exercisabl